This inventor holds 1 USPTO granted patent. Top assignees: Toyobo Co., Ltd., Xonex Laboratories, Inc.. Active years: 1993.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 1993
Title: The Innovations of Toshio Tuchida
Introduction
Toshio Tuchida is a notable inventor based in Shiga, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-inflammatory and analgesic compounds. His work has implications for treating auto-immune diseases, showcasing the intersection of natural extracts and synthetic chemistry.
Latest Patents
Tuchida holds a patent for "Anti-inflammatory and analgesic compounds, related compositions." This application relates to a composition that is anti-inflammatory, immunosuppressive, and analgesic. The compound is derived from ant venom extract, which has been purified to remove non-active components found in crude extracts. Additionally, a synthetic venom has been prepared from various components. The pharmaceutical composition has demonstrated effectiveness in treating and alleviating symptoms of auto-immune diseases, particularly rheumatoid arthritis.
Career Highlights
Throughout his career, Tuchida has worked with prominent companies such as Toyobo Co., Ltd. and Xonex Laboratories, Inc. His experience in these organizations has allowed him to refine his expertise in pharmaceutical development and innovation.
Collaborations
Tuchida has collaborated with notable individuals in his field, including Duane R. Schultz and Kazuo Watanabe. These collaborations have likely contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Toshio Tuchida's work in developing anti-inflammatory and analgesic compounds highlights his innovative approach to addressing complex medical challenges. His contributions to the field of pharmaceuticals are significant and continue to impact the treatment of auto-immune diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile